A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
Latest Information Update: 20 Dec 2024
At a glance
- Drugs Cariprazine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie; Allergan
Most Recent Events
- 18 Feb 2022 Planned End Date changed from 17 Dec 2022 to 1 Apr 2025.
- 18 Feb 2022 Planned primary completion date changed from 17 Dec 2022 to 1 Apr 2025.
- 18 Feb 2022 Status changed from active, no longer recruiting to recruiting.